ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
WILMINGTON, Del.--(BUSINESS WIRE)-- Constructive high-level outcomes from the open-label Section III CHAMPION-NMOSD trial confirmed that ULTOMIRIS® (ravulizumab-cwvz) achieved a statistically ...
